Gilead could be sitting on biggest blockbuster ever
A new drug from Gilead Sciences, bringing good news to the 170 million people suffering from hepatitis C all over the world, could garner more than USD 15 billion for the US-based company.
by Henrik Tüchsen
The best-selling drug in the history of commercial medicine could be on the horizon in the form of the new Hepatitis C drug Sovaldi (sofosbuvir) from US biopharma group Gilead Sciences, chief advisor Michael Borre, Nordea Investment Strategy & Advice, tells Medwatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Major investor: Breakthrough in hepatitis battle
For abonnenter
Santaris bags millions and new US CEO
For abonnenter
